Phase III trial of BC 819 in patients with bladder cancer that was resistant to initial treatment with BCG.
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs BC 819 (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms BCG Refractory
- Sponsors BioCancell Therapeutics
- 14 Aug 2017 This trial will be performed under a Special Protocol Assessment provision of the US FDA, as reported in a BioCancell Therapeutics media release
- 14 Aug 2017 According to a BioCancell Therapeutics media release, this trial is expected to be initiated in 2017.
- 10 Sep 2015 Planned initiation date changed from 1 Dec 2015 to 1 Jan 2016 according to a BioCancell Therapeutics media release.